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RESEARCH ARTICLE
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To determine survival in afatinib-treated patients after treatment with first-generation EGFR
tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant
tumors.
Methods
Characteristics and survival of patients treated with afatinib after resistance to erlotinib or
gefitinib in two large Dutch centers were collected. Whole exome sequencing (WES) and
pathway analysis was performed on available pre- and post-afatinib tumor biopsies and nor-
mal tissue.
Results
A total of 38 patients were treated with afatinib. T790M mutations were identified in 22/29
(76%) pre-afatinib treatment tumor samples. No difference in median progression-free-sur-
vival (2.8 months (95% CI 2.3–3.3) and 2.7 months (95% CI 0.9–4.6), p = 0.55) and median
overall-survival (8.8 months (95% CI 4.2–13.4) and 3.6 months (95% CI 2.3–5.0), p = 0.14)
were observed in T790M+ patients compared to T790M- mutations.
Somatic mutations in TP53, ADAMTS2, CNN2 and multiple genes in the Wnt and PI3K-
AKT pathway were observed in post-afatinib tumors of six afatinib-responding and in one
non-responding patient. No new EGFR mutations were found in the post-afatinib samples of
the six responding patients. Further analyses of post-afatinib progressive tumors revealed
28 resistant specific mutations in six genes (HLA-DRB1, AQP7, FAM198A, SEC31A,
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CNTLN, and ESX1) in three afatinib responding patients. No known EGFR-TKI resistant-
associated copy number gains were acquired in the post-afatinib samples.
Conclusion
No differences in survival were observed in patients with EGFR-T790M treated with afatinib
compared to those without T790M. Tumors from patients who had progressive disease dur-
ing afatinib treatment were enriched for mutations in genes involved in Wnt and PI3K-AKT
pathways.
Introduction
Most patients with advanced non-small cell lung carcinoma (NSCLC) with epidermal growth
factor receptor (EGFR) activating mutations will develop resistance after 6–9 months of treat-
ment with first generation reversible tyrosine kinase inhibitors (TKIs) such as erlotinib or gefi-
tinib[1,2]. The most common resistance mechanism is caused by the T790M gatekeeper
mutation, and is detected in about half of the patients. Additional resistance-associated mecha-
nisms are MET amplification, HER2mutations, transformation to small-cell lung cancer,
expression of IGFR1, or alternative pathways to maintain PI3K/Akt signalling[3–7].
Because afatinib showed effectiveness in erlotinib resistant lung cancer models, afatinib
effectiveness was studied in the Lux-Lung 4 study[8]. In this study patients with acquired resis-
tance to first generation EGFR-TKIs exhibited a low response rate to afatinib and consequently
the study did not meet its primary endpoint[9]. Reported resistance mechanisms to afatinib
after first generation TKI are other mutations in EGFR (e.g. V843I), FGFR1 amplification,
upregulation of IL6R/JAK1/STAT3, glycolysis and Src pathways, and autophagy[10–17].
Pooled analysis of the Lux-Lung 3 and 6 trials showed a superior overall survival (OS) for
first-line afatinib of 31.7 months for exon 19del EGFRmutations versus 20.7 months for the
chemotherapy group (HR 0.59 (95%CI 0.45–0.77); p = 0.001). In contrast, no significant effect
on OS of afatinib was observed in the L858R group (22.1 months versus 26.9 months in the
chemotherapy group (HR 1.25 (95%CI 0.92–1.71); p = 0.16)[18]. Direct comparison of first-
line gefitinib vs. afatinib treated patients revealed a significantly improved progression free
survival (PFS) for patients treated with afatinib in a phase 2b trial[19]. Treatment of
EGFRL858R/T790M mutant cell lines with rociletinib and osimertinib, targeting T790M, revealed
a strong inhibition on cell growth[20]. In lung cancer patients, tumour responses with these
compounds were observed in 58% and 68% of patients with T790M mutation, respectively
[21,22].
The T790M mutation plays a role as mechanism of resistance after first line treatment with
afatinib as well[23]. However, in an Eastern Asian study, T790M played no role in treatment
outcome or the prognosis of patients treated with second-line afatinib indicating a similar
effect on both T790M positive and negative tumour clones[24]. The development of late occur-
ring T790M clones in tumours may go along with other resistant mechanisms than early devel-
oping T790M clones.
In this study we analysed survival of mostly white patients treated with afatinib after becom-
ing resistant to erlotinib or gefitinib. In addition, we investigated the development of afatinib
resistant associated mutations using whole exome sequencing (WES) in a subset of patients.
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Materials and methods
Patient selection
Patients with relapsed advanced NSCLC whose tumour had progressed following initial dis-
ease control for more than 12 weeks with gefitinib or erlotinib and subsequently treated with
afatinib 40 mg daily, partly on a compassionate use program, were enrolled, in two Dutch Uni-
versity Medical Centres (Free University Medical Centre and University Medical Centre Gro-
ningen)[25]. Patient characteristics including number of treatment lines, duration of previous
EGFR-TKI exposure, the duration of afatinib use and PFS and OS were recorded. Informed
consent for tumour tissue from all patients was obtained before biobanking and retrieval from
the Groningen Pathology biobank and VUMC Pathology biobank. All patient data were anon-
ymised and de-identified prior to analysis. The authors were not informed about identification
variables. The study was approved by the Medical Ethical Committee of the University Medical
Centre Groningen and conducted in accordance with the provisions of the Declaration of Hel-
sinki and Good Clinical Practice guidelines. Due to the retrospective nature of this study on
biobanking material, under Dutch Law for human medical research (WMO), no specific writ-
ten permission was compulsory from the Institutional Review Board.
Tumour response measurement
Tumour responses were assessed by comparing CT of chest and abdomen before start of afati-
nib, and every 6 weeks during treatment using RECIST version 1.1 criteria[26]. This means
that if there was more than 30% shrinkage of the tumour and metastases, this was called a par-
tial response (PR). If more than 20% growth of the tumour was found, this was called progres-
sive disease (PD). Otherwise we called this stable disease (SD).
Tumour biopsies and diagnostic molecular analysis
Tumour biopsies were tested for the presence of EGFRmutations before and after treatment
with erlotinib or gefitinib. Re-biopsies were taken for WES prior to start of afatinib and upon
subsequent tumour progression. Paired blood or normal tissue was used as control to filter for
personal variants. Briefly, 3-micron paraffin embedded tumour tissue sections were stained
with haematoxylin and eosin and assessed for tumour content. Subsequent tissue sections of
10 micron were used for DNA isolation. Diagnostic testing for mutations was performed using
high resolution melting analysis (HRM) for EGFR exons 18, 19, 20 and 21 (CCDS5514.1), for
KRAS exon 2 for codon 12, 13, 61 (CCDS8702.1) and for BRAF exon 15 (NM_004333)[27,28].
PCR products with an abnormal HRM curve were re-amplified and subjected to Sanger
sequencing to identify the mutation. ALK and ROS1 translocations were determined by Abbott
FISH tests (Abbott 06N38-020 and Abbott 08N29-020), respectively.
Whole exome sequencing
In cases of tumour content less than 50%, laser microdissection (LMD6000, Leica, Wetzlar,
Germany) was used. DNA from FFPE samples for WES was isolated using ReliaPrep™ FFPE
gDNAMiniprep System kit (Promega, Madison, USA) following the protocol of the manufac-
turer. A standard salt-chloroform protocol was used to isolate DNA from blood. Quality con-
trol and WES were performed by BGI (BGI Tech Solutions Co. Ltd, Hong Kong). Raw image
files were processed by Illumina base-calling Software 1.7 for base-calling with default parame-
ters (Illumina Inc., San Diego, USA).
Reads were aligned to the human 1000 genomes reference based on the GRCh37 build
using BWA 5.9rc[29]. Picard tools were used for format conversion and marking duplicate
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reads. Genome Analysis Toolkit (GATK) was used for indel realignment and base score quality
recalibration (BSQR) by Molgenis Compute 4[30,31]. After using custom scripts in the VCF
tools library, variant calling was performed using the GATK unified genotype and variant
annotation by using SNPEFF/SNPSIFT 3.5 with the ensembl release 74 gene annotations
http://www.ensembl.org/index.html), dbNSFP2.3, and GATK with annotations from the Data-
base of Single Nucleotide Polymorphisms (dbSNP) Bethesda (MD): National Centre for Bio-
technology Information, National Library of Medicine (dbSNP Build ID: 137) and
CosmicCodingMuts_v62[32–35]. For mutations with a moderate impact according to
SNPEFF, we used the CADD value to discriminate between mutations with a possible (CADD
score >10) or a probable effect (CADD >20) on protein function. Exome sequencing data
have been deposited on European Nucleotide Archive (ENA) website and are available under
accession number: PRJEB21459 (http://www.ebi.ac.uk/ena/data/view/PRJEB21459).
Identification of afatinib resistance associated mutations
Different criteria were used to identify mutations associated with resistance to afatinib treat-
ment. First, we eliminated variants with a total read count of less than 10 in corresponding
normal DNA, as we were not able to exclude them as personal variants (step 1). Then, we
excluded germline variants based on mutant read count of more than one and a total read
count of 10–49, or mutant read count of more than two and a total read count of50 in the
normal DNA (steps 2 and 3). The remaining variants were regarded as true somatic mutations.
Next, we filtered out variants with less than 10x coverage in either primary or resistant biopsies
(step 4), as read counts for these variants are too low to be used for identification of afatinib
resistance associated mutations.
As we did not have pre-afatinib tumour sample for all seven patients, that also had post-afa-
tinib samples, we followed two different strategies to identify potential resistance-related muta-
tions: a) for all seven patients with adequate tumour samples we generated a list of genes
having a mutation in the resistant sample irrespective of having a pre-afatinib sample or not,
b) for 3 out of 7 patients with both pre- and post-afatinib samples, we selected variants with a
more than two times higher mutant read frequency (MRF) in the resistant versus the primary
biopsy (MRFR>2
MRFP; step 5).
In the final step of both analyses, we only included variants with a mapping quality >20
and a quality score>20. Genes found in this analysis were browsed in the Exome Aggregation
Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [accessed JUL-
2016] to screen for any remaining known single nucleotide variants (SNVs). The COSMIC
database was used to compare identified mutations in our cohort to the reported somatic
mutations in cancer (http://cancer.sanger.ac.uk/cosmic) [accessed AUG-2016].
Pathway analysis
Partek Genomics Suite 6.6 (Partek Inc., St Louis, MO) was used to link mutated genes to either
particular pathways only or whether they belonged to the same pathways.
WES-based copy number variant analysis (CNV)
Pseudo probe data were generated with VarScan2 and Samtools as described previously by
Koboldt et al. and Li et al.[36,37]. Briefly, for each sample the pseudo probe derived GC-nor-
malized log2 copy number ratios were generated by dividing the read counts of the tumour
sample by the read counts of the corresponding normal sample. All alignments with a mapping
quality greater than 40 in combination with a minimal segment size of 2kb and a maximal seg-
ment size of 5kb with a mean coverage of at least one were used to calculate the log2 ratios.
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CNV plots of the post-afatinib tumour were compared to the CNV plot of the pre-afatinib
tumour of the same patient by a combination of calculated ratios and visual inspection.
Statistical analysis
Descriptive statistics were used for the patient characteristics. Objective tumour response rate
(ORR) was defined as the best response to treatment of complete response (CR) or partial
response (PR) according to RECIST 1.1[26]. PFS was defined as the time from start of first
generation TKI or start of afatinib in calculating PFS of erlotinib and gefitinib or afatinib treat-
ment, respectively, until progressive disease (PD) according to RECIST 1.1 or death and OS
was defined as the time from start of these treatments until death or lost to follow up. Patients
who had not progressed at data cut-off were censored at the last day of follow-up. PFS and OS
were estimated with Kaplan-Meier survival curves using log-rank test for estimating group dif-
ferences. Chi-square Test was used to compare group variables. P-values <0.05 were consid-
ered significant. Statistical analyses were performed with SPSS-Statistics version 22.0 (IBM
corporation, Armonk, NY, USA).
Results
Study population
Between April 2009 and January 2014, 38 patients with advanced adenocarcinoma of the lung,
from two Dutch university hospitals, were treated with afatinib (S1 Fig). Follow-up was more
than 18 months after the last patient was included. All patients received gefitinib or erlotinib
prior to afatinib, two patients received erlotinib, followed by gefitinib. A platinum doublet was
given as first line treatment to 24 patients before treatment with first generation TKI and afati-
nib (Fig 1).
Efficacy of 1st line and 2nd line TKI treatments
Median PFS on first-line erlotinib or gefitinib TKI treatment in those who turned out to be
T790M positive (n = 22) and negative (n = 7) in later biopsies showed a trend to be different,
13.3 months (95% CI., 10–17) and 8.1 months (95% CI., 0–16) respectively (p = 0.06; Fig 1).
Tumour response rate of all 38 patients on second line afatinib was 18% and the disease
control rate was 79%. Median PFS on afatinib was 2.8 months (95% CI., 2.3–3.2) and median
OS was 6.9 months (95% CI., 1.5–12.4).
Survival by mutation type in afatinib treated patients
Median PFS of afatinib treated patients with (n = 22) and without (n = 7) T790M mutation
was similar with 2.8 months (95% CI 2.3–3.3) and 2.7 months (95% CI 0.9–4.6), respectively
(p = 0.55; Fig 1). Median OS was numerical better in the T790M positive as compared to the
T790M negative group, although not significant (8.8 months (95% CI, 4.2–13.4) and 3.6
months (95% CI, 2.3–5.0); p = 0.14; Fig 2).
EGFR mutational analysis
The first biopsy was taken before start of any TKI treatment (n = 38). Thirty-three patients had
activating EGFRmutations, the most common mutation was a deletion in exon 19 (87%; n = 24)
(Table 1); no T790M mutations were observed in any of the biopsies taken before EGFR-TKI.
Four patients with wild type EGFR and one patient with no test result available were included
based on Jackman’s criteria (TKI treatment with at least stable disease for 6 months)[25]. None
of those five patients had KRAS or BRAFmutations or ALK and ROS1 translocations.
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A second biopsy taken after failure on erlotinib or gefitinib was available of twenty-nine
EGFR+ patients. In 22/29 (76%) patients with a known activating EGFRmutation the T790M
mutation was detected as a second mutation. The presence of a T790M mutation was signifi-
cantly more common in patients treated with erlotinib alone (18/19; 95%) compared to
patients treated with gefitinib alone (2/8; 25%, p<0.001; Table 2). The two patients treated
with erlotinib and gefitinib were excluded from this comparison. No cancer cell transforma-
tion has been observed in our population.
Whole exome sequencing (WES)
Out of the 18 patients with a post-afatinib biopsy, there was enough tumour tissue to perform
WES in six patients. Normal, pre- and post-afatinib samples were available in 3 of the 6 respond-
ing patients (#2, 5 and 6) and only normal and post-afatinib samples with sufficient DNA quality
were available from the other three patients (#1, 4 and 7). In only one (patient #3) out of nine
non-responders to afatinib, there was enough tumour tissue in the pre-afatinib biopsy. Of the
non-responding patient we analysed pre-afatinib normal and tumour tissue samples.
In the initial analyses we focused on recurrently mutated genes found in at least 2 of the 7
biopsies irrespective of presence of the mutation in the pre-treatment biopsy. This revealed
presence of 284 mutations in 68 genes (S1 Table). According to putative damaging effect
according to CADD a high score (>20) was found for 27 mutations in 25 genes, e.g. TP53,
Fig 1. Median PFS for sequential treatments in T790M positive and negative NSCLC patients. After first generation EGFR-TKI, 22
patients had a T790M and 7 did not. All patients received afatinib, afterwards.
https://doi.org/10.1371/journal.pone.0182885.g001
Fig 2. Median PFS in OS axis for sequential treatments in T790M positive and negative advanced
NSCLC patients. Survival outcome of afatinib treatment is shown after first generation EGFR-TKI treatment.
The X-axis represents the overall survival. The bars indicate the progression free survival for afatinib.
https://doi.org/10.1371/journal.pone.0182885.g002
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DYNC2H1, MGA, USH2A, ROBO2, TEX15,ADAMTS2,CUL7, IL33, ADAMTS12,CNN2,
CNKSR3, LAMA3, EML6, TTN,KNDC1,EPB41, PKHD1L1,KLHL23, EVPL, CACNA2D1,
CDC27,KCNT2, ASTN2 and MROH2B. A moderate CADD score (10–20) and/or recurrent
mutations were found for 110 mutations in 45 genes, e.g., OR8U1,MUC16,MUC6,
Table 1. EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.
EGFR mutation First biopsy (n = 38) Pre-afatinib biopsy (n = 33) Post-afatinib biopsy (N = 18) WES (N = 7)
Exon 18 1 0 1 0
Exon 19 24 4 5 2
Exon 19 + T790M 18 6 1
WT 1
Exon 21 7 2 2 0
Exon 21 + T790M 4 2 2
Exon 18 + 20 1 1 0 0
WT 4 4 2 0
Exon 18 + 21 +T790M 1
Mutation analysis not possible 1 0 0 0
A diagnostic biopsy taken before erlotinib and/or gefitinib treatment is called first biopsy; A biopsy after first generation EGFR-TKI is called pre-afatinib
biopsy. Biopsy taken in patients who responded to afatinib and underwent a biopsy afterwards is called post-afatinib biopsy. WT: wild type.
https://doi.org/10.1371/journal.pone.0182885.t001
Table 2. Patient characteristics of the afatinib treated group according to T790M mutation.
T790M + (N = 22) T790M − (N = 7) P-value












Smoking history (at start afatinib treatment) 0.33
Never smoker 10 5
Ex-smoker 10 1
Current smoker 0 0
Unknown 2 1





EGFR TKI before afatinib <0.001
erlotinib 18 1
gefitinib 2 6
both subsequently 4 1
https://doi.org/10.1371/journal.pone.0182885.t002
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ANKRD36C,HLA-DRB5, DYNC2H1, NEFH, FASLG, MUC5B, PRSS3,HYDIN, MGA, USH2A,
TAS2R43, GRP98, C4BPB,DOCK2, INVS,CUL7,NHSL2, USP24, TPSB2,MUC12,OR2T4,
CNN2,CNKSR3, LAMA3, TTN,KNDC1,EPB41, EVPL, FZR1, CACNA2D1, CDC27,KCNT2,
EMP2, MST1, ARHGAP32,NLGN4X,HLADQA1,HERC2,ASTN2, SP8, PRSS1 and MROH2B.
CNN2 is the only gene with an identical high CADD score mutation in 2 patients. Some of the
other recurrently mutated genes had mixed high and moderate CADD scores. In total, 137
mutations in 48 genes were identified as potentially involved in afatinib resistance.
In patient #7 treated with afatinib according to Jackman’s criteria, without a known EGFR
mutation, WES revealed activation mutations in EGFR, e.g. G719C and a L861Q. In the other
six patients, no new EGFRmutations were identified. For the three pre-afatinib samples this
was consistent with the targeted diagnostic mutation tests.
In patients #2, 5, and 6 (Table 3) WES data of normal tissue, pre- and post-afatinib tumour
samples could be analysed.
Four hundred forty five mutations in 367 genes (range 87–216) had higher MRF, or were
specific, for the post-afatinib treatment sample. Mutations in these genes might have contrib-
uted to the observed afatinib resistance. Six genes, with in total 28 mutations, were recurrently
mutated in at least two out of three patients, i.e. HLA-DRB1, AQP7, FAM198A, SEC31A,
CNTLN, and ESX1.
Most of the mutations observed in HLA-DRB1 were also present in the ExAc database and
therefore appear to be less important. The other mutations, absent in the ExAc database but
present in the COSMIC database (in different tumour types), might be relevant, such as p.
W38fs in HLA-DRB1, p.Q30fs in AQP7, p.C135R in TP53, p.Q220 in HLA-DRB5, p.G8V in
PRSS3, p.S1155R in USH2A and p.V521I in KCNT2. The p.K41T mutation in HLA-DRB1, p.
IT255T and p.Q136E in TP53 and p.P2811S in USH2A are also described in human lung can-
cer samples. The p.P95S mutation in AQP7 was observed in patients #1 and #5.
Pathway analysis of all genes mutated in any of the 7 analysed patients indicated that most
of the mutated genes were members of Wnt signalling (S2 Fig) and PI3K-AKT (S3 Fig) path-
ways. In addition, we observed mutations in two genes of the glycolysis pathway (Table 4). We
did not identify mutations in genes related to the pathways known to be associated with afati-
nib resistance, e.g. autophagy and IL6R/JAK/STAT.
Copy number variations
We observed only a few changes in copy number variations (CNV) between the pre- and post-
afatinib samples. In patient #2 copy number gain (CNG) of part of chromosome 5, 8, 11 and 16
and loss of part of chromosome 4 and 14 was observed (S4A Fig). In patient #5 no differences
in CNV between pre- and post-afatinib biopsies was observed (S4B Fig). In patient #6, copy
number loss was seen only for part of chromosome X (S4C Fig). Specifically, no CNV aberra-
tions in MET, FGFR1, Src or genes involved in the IL6/JAK1/STAT3 pathway were found.
Discussion
In this study we investigated afatinib resistance in patients with relapsed advanced NSCLC
whose tumour had progressed on gefitinib or erlotinib and subsequently were treated with afa-
tinib. In 38 patients with an EGFRmutation or treated with TKIs according to Jackman’s crite-
ria we first determined the relevance of erlotinib and gefitinib in inducting T790M mutation
in EGFR. The exon 20 T790M mutation was detected under EGFR-TKI selection pressure in
re-biopsies of 22/29 (76%) patients in our cohort. This percentage is slightly above the upper
range that has been reported in the literature (25–63%)[38–40]. The percentage of T790M
+ patients was significantly higher in the erlotinib treated as compared to the gefitinib treated
OS for afatinib in NSCLC treated patients and resistant mechanisms upon disease progression
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patients. In the literature there is a trend that T790M mutations are numerically higher in
patients who received erlotinib[41]. The duration of first line reversible TKIs did not influence
the occurrence of a T790M mutation. In our cohort of afatinib treated patients, PFS (2.8
months) and OS (9.2 months) were similar to the Lux-Lung 1 study[42]. We did not find an
influence of the pre-afatinib treatment induced T790M mutation on response outcome (PFS
or OS) on second line afatinib treatment. This is consistent with the study of Sun et al. on an
Asian population. In contrast Landi et al. found no tumour response with afatinib in T790M
positive patients. In the current literature discrepancy is observed in the tumour response to
afatinib in T790M positive patients[24,43].
To understand molecular events underlying progression of disease on afatinib treatment,
WES was performed in all patients with sufficient tumour tissue to identify known and novel
resistance mechanisms. We observed 68 recurrently mutated genes in 7 different patients with
Table 3. Recurrently mutated genes in tumors from patients who progressed under afatinib.
GENE PATIENT CHROM POS REF ALT AA CHANGE CADD score
HLA-DRB1 #2 6 32552130 C A R42S 0.145
32552131 C G R42T 0.005
#6 32552134 T G K41T 10.93
#3 32552130 C A R42S 0.145
32552132 T A R42W 10.52
#4 32548544 T G I248L 16.04
#7 32552130 C A R42S 0.145
32552131 C G R42T 0.005
32552137 G C P40R 0
32552138 G C P40A 0.005
32552143 C T W38* 13.84
32552144 A C W38G 3.518
AQP7 #2 9 33385808 G T N194K 15.08
#5 33385709 C T V96I 9.787
33385712 G A P95S 10.22
33385690 C T R234S 14.5
33385698 A G L231P 16.61
#1 33385712 G A P95S 10.22
#4 33395131 TG T Q30 NA
FAM198A #2 3 43074734 C A P327T 9.704
#6 43074337 G T W194C 14.09
SEC31A #5 4 83803067 C T R8H 27.8
#6 83784534 CT C E482 NA
CNTLN #2 9 17366624 TGAA T E633 NA
#5 17236574 TG T A280 NA
17236576 C A A280E 5.077
ESX1 #2 X 103497493 G C R175G 11.68
#6 103498982 C A G120V 14.79
Tumor samples were from 3 patients (#2, #5 and #6) with WES data of normal, primary and resistant tumors and from patients with samples from resistant
tumors only.
chrom, chromosome; pos, basepair location; ref/alt, reference and altered nucleotides at mutated position; AA change, amino acid change; CADD,
Combined Annotation Dependent Depletion score; CADD score10 indicates a position within the top 10% most deleterious mutations. A score of20
indicates a position within the top 1% most deleterious mutations.
https://doi.org/10.1371/journal.pone.0182885.t003
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progression under afatinib, of which 137 mutations in 48 genes are probably involved in afati-
nib resistance based on moderate or high CADD score. The R287Q mutation in CNN2 is note-
worthy based on the high CADD score and being identified in two patients. CNN2 has been
described in prostate cancer and is involved in cell migration and cell morphology[44]. This
gene is probably involved in rectal cancer as well[45]. Post-afatinib specific mutations were
observed in HLA-DRB1, AQP7, FAM198A, SEC31A,CNTLN and ESX1.
The observed resistance associated mutations were present in a broad range of genes.
Therefore, we explored if these genes clustered in specific pathways that might play a role in
the progression of disease while being on afatinib treatment. We found that most of the genes
with mutations were part of the Wnt and/or PI3K-AKT pathways. Mutations in genes related
to the Wnt pathway were also implicated in erlotinib resistance in EGFRmutation positive
lung cancer cell lines[46,47]. In gastric cancer for example, a role for Wnt signalling has been
observed to influence disease behaviour[48].
Inhibiting the Wnt pathway is an attractive treatment option for patients with resistant can-
cers and is now tested in phase I trials. The PI3K-AKT pathway has not been associated with
afatinib resistance previously, except perhaps the hint observed in gefitinib resistant NSCLC
patients treated with Paris Saponins which induced apoptosis via the PI3K-AKT pathway in
the tumour cells[49]. In melanoma, for example, AKT signalling is an important resistant
mechanism in BRAF positive cancer cells [50].
CNVs of different genes have been associated with resistance in EGFRmutant lung cancer
[51]. However, in our cohort of afatinib resistant patients, no known specific afatinib resis-
tance-related CNVs were observed. Together with the WES data, this suggests that in our
patients, mutations in EGFR or IGFR1, genomic aberrations in MET, FGFR1 amplification,
mutations in SRC or in the IL6R/JAK1/STAT3 pathway, previously reported as resistance
mechanisms by association in few patients or in cell lines, were not observed in our study to be
involved in afatinib resistance[5,10].
Table 4. Overview of significantly involved pathways in patients’ progressive disease on afatinib and the involved mutated genes.
Nr. of patient sample N/P/R N/R N/P
#2 #5 #6 #1 #4 #7 #3









PI3K-AKT COL4A4 ITGA2 PPP2R2B EGFR LAMC3 EGF EGFR EGFR TP53 KDR
EGFR PIK3CA EGFR LAMB3 FASLG RELN
VWF PIK3CG COL1A2 PTEN FASLG
TSC2 COL4A5 FASLG TP53
TP53 TP53
A: resistant biopsy specific based on MRF R >2x MRF P, B: mutation present in both pre and post afatinib biopsy based on MRF R <2x MRF P and MRF
R > 0. C: mutation in resistant biopsy based on MRF R > 0, D: mutation in pre-afatinib biopsy in non-responding patient based on MRF P > 0; italic: present
in other primary samples. N: normal tissue or buffy coat, P: biopsy before afatinib treatment, R: biopsy after afatinib treatment.
https://doi.org/10.1371/journal.pone.0182885.t004
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In conclusion, no differences in survival were observed in patients with EGFR T790M
treated with afatinib compared to those without T790M. Potential mechanism of resistance to
afatinib treatment might be related to mutations in HLA-DRB1, AQP7, TP53,HLA-DRB5,
PRSS3,USH2A,KCNT2 and CNN2 and to mutations in genes of the Wnt and PI3K-AKT
pathways.
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pemetrexed.
(TIF)
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different mutations found in different samples. Multiple mutated genes involved in the Wnt
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(TIF)
S3 Fig. PIK3-AKT signaling pathway involved in afatinib resistant tumours. Color boxes
are the different mutations found in different samples.
(TIF)
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